JP2012523437A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523437A5
JP2012523437A5 JP2012504924A JP2012504924A JP2012523437A5 JP 2012523437 A5 JP2012523437 A5 JP 2012523437A5 JP 2012504924 A JP2012504924 A JP 2012504924A JP 2012504924 A JP2012504924 A JP 2012504924A JP 2012523437 A5 JP2012523437 A5 JP 2012523437A5
Authority
JP
Japan
Prior art keywords
methyl
isopropyl
amino
carboxylic acid
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012504924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523437A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030760 external-priority patent/WO2010120695A2/en
Publication of JP2012523437A publication Critical patent/JP2012523437A/ja
Publication of JP2012523437A5 publication Critical patent/JP2012523437A5/ja
Pending legal-status Critical Current

Links

JP2012504924A 2009-04-13 2010-04-12 認知障害の治療のための5−ht4受容体アゴニスト化合物 Pending JP2012523437A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US61/168,741 2009-04-13
US29255910P 2010-01-06 2010-01-06
US61/292,559 2010-01-06
PCT/US2010/030760 WO2010120695A2 (en) 2009-04-13 2010-04-12 5-ht4 receptor agonist compounds for treatment of cognitive disorders

Publications (2)

Publication Number Publication Date
JP2012523437A JP2012523437A (ja) 2012-10-04
JP2012523437A5 true JP2012523437A5 (enExample) 2013-04-11

Family

ID=42237213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504924A Pending JP2012523437A (ja) 2009-04-13 2010-04-12 認知障害の治療のための5−ht4受容体アゴニスト化合物

Country Status (24)

Country Link
US (2) US8404711B2 (enExample)
EP (1) EP2419104B1 (enExample)
JP (1) JP2012523437A (enExample)
KR (1) KR20120017421A (enExample)
CN (2) CN105832735A (enExample)
AU (1) AU2010236734B2 (enExample)
BR (1) BRPI1013777A8 (enExample)
CA (1) CA2758321A1 (enExample)
CY (1) CY1119800T1 (enExample)
DK (1) DK2419104T3 (enExample)
ES (1) ES2654930T3 (enExample)
HR (1) HRP20180018T1 (enExample)
HU (1) HUE038141T2 (enExample)
IL (1) IL215660A0 (enExample)
LT (1) LT2419104T (enExample)
MX (1) MX2011010782A (enExample)
NO (1) NO2419104T3 (enExample)
PL (1) PL2419104T3 (enExample)
PT (1) PT2419104T (enExample)
RU (1) RU2569056C2 (enExample)
SI (1) SI2419104T1 (enExample)
SM (1) SMT201800036T1 (enExample)
WO (1) WO2010120695A2 (enExample)
ZA (1) ZA201107490B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CN105687190A (zh) 2008-11-19 2016-06-22 福拉姆医药股份有限公司 用(R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺及其可药用盐治疗认知障碍
PE20120324A1 (es) * 2009-05-11 2012-04-17 Envivo Pharmaceuticals Inc Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
KR20180101641A (ko) 2010-05-17 2018-09-12 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
WO2014027864A1 (ko) 2012-08-16 2014-02-20 경희대학교 산학협력단 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균
SG11201909895UA (en) 2017-05-24 2019-11-28 H Lundbeck As Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
CN116585316A (zh) 2017-06-01 2023-08-15 卫材R&D管理有限公司 包含pde9抑制剂的药物组合物
CN116473962A (zh) 2017-06-02 2023-07-25 富士胶片富山化学株式会社 脑萎缩预防或治疗剂
EP3661518B1 (en) 2017-07-31 2024-08-28 Alfasigma S.p.A. Methods of treating symptoms of gastroparesis using velusetrag

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249091A1 (en) * 2000-03-03 2001-09-17 Eisai Co. Ltd. Novel methods using cholinesterase inhibitors
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Similar Documents

Publication Publication Date Title
JP2012523437A5 (enExample)
ES2765200T3 (es) Tratamiento de efectos secundarios de trastornos motores y de movimiento asociados a tratamientos de la enfermedad de Parkinson
RU2011146032A (ru) Соединения-агонисты рецептора 5-ht4 для лечения расстройств познавательной способности
JP2019059760A5 (enExample)
JP2015528471A5 (enExample)
JP2017531033A5 (enExample)
JP2020505408A5 (enExample)
JP2016535795A5 (enExample)
JP2014517050A5 (enExample)
CA2641917A1 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
JP2012530779A5 (enExample)
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
JP2014502641A5 (enExample)
JP2011524850A5 (enExample)
JP6163165B2 (ja) レボセチリジンまたはその医薬的に許容される塩およびモンテルカストまたはその医薬的に許容される塩を含む経口投与用安定医薬製剤
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2014511892A5 (enExample)
JP2013535505A5 (enExample)
JP2012508734A5 (enExample)
JP2017537954A5 (enExample)
JP2015521617A5 (enExample)
JP2021505575A5 (enExample)
JP2013518914A5 (enExample)
JP2016514688A5 (enExample)
RU2013153140A (ru) Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат